Golidocitinib

Lymphoma, Extranodal NK-T-Cell

Ruijin HospitalSmall moleculePhase 2Active

CCC

53/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 38/ 100
Competitive Position: 95/ 100

Competitive context

7 Active assets in the Lymphoma, Extranodal NK-T-Cell cohort.

Asset / Sponsor	Phase	Rating
Cyclophosphamide International Extranodal Lymphoma Study Group (IELSG)	Phase 3	BB
PREDNISONE TABLETS Sun Yat-sen University	Phase 3	BB
Eloxatin Sun Yat-sen University	Phase 3	BB
ETOPOSIDE Sichuan University	Phase 3	BB
Inno-206 Sun Yat-sen University	Phase 3	BB

View all 24 →

Same molecule, other indications

Golidocitinib is also rated in:

non-small cell lung carcinomaDormant

BB

Indicative ·

68 / 100

peripheral T-cell lymphoma, not otherwise specifiedDormant

B

Indicative ·

63 / 100

extranodal nasal NK/T cell lymphomaDormant

B

Indicative ·

60 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.